Steven C. Jones Sells 1,691 Shares of NeoGenomics, Inc. (NASDAQ:NEO) Stock
NeoGenomics, Inc. (NASDAQ:NEO) Director Steven C. Jones sold 1,691 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $25.00, for a total transaction of $42,275.00. Following the completion of the transaction, the director now owns 245,234 shares in the company, valued at approximately $6,130,850. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
NEO stock traded down $1.13 during trading on Tuesday, hitting $21.67. 1,394,917 shares of the company traded hands, compared to its average volume of 1,036,988. NeoGenomics, Inc. has a 1 year low of $11.05 and a 1 year high of $26.89. The company has a market cap of $2.29 billion, a PE ratio of 166.69 and a beta of 0.97. The stock’s 50-day simple moving average is $24.67 and its 200 day simple moving average is $22.25. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.67 and a quick ratio of 4.52.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, July 30th. The medical research company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.02. The business had revenue of $101.71 million for the quarter, compared to analyst estimates of $97.32 million. NeoGenomics had a return on equity of 4.97% and a net margin of 0.57%. The business’s quarterly revenue was up 50.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.05 EPS. Research analysts expect that NeoGenomics, Inc. will post 0.19 earnings per share for the current year.
NEO has been the subject of a number of recent research reports. ValuEngine lowered shares of NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. Needham & Company LLC set a $27.00 price objective on shares of NeoGenomics and gave the company a “buy” rating in a report on Wednesday, July 31st. Raymond James increased their price objective on shares of NeoGenomics from $23.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 31st. BidaskClub raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Friday, July 19th. Finally, Benchmark set a $27.00 target price on shares of NeoGenomics and gave the company a “buy” rating in a research report on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $23.78.
Institutional investors and hedge funds have recently bought and sold shares of the stock. NEXT Financial Group Inc boosted its stake in shares of NeoGenomics by 200.0% during the 2nd quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock worth $59,000 after acquiring an additional 1,800 shares in the last quarter. Captrust Financial Advisors purchased a new position in NeoGenomics during the second quarter worth approximately $66,000. Winslow Evans & Crocker Inc. acquired a new stake in NeoGenomics in the second quarter valued at approximately $92,000. Oregon Public Employees Retirement Fund acquired a new stake in NeoGenomics in the first quarter valued at approximately $132,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in shares of NeoGenomics in the first quarter valued at approximately $141,000. Hedge funds and other institutional investors own 84.84% of the company’s stock.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Story: What is the CBOE Russell 2000® Volatility Index?
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
|CryptoCurrency||USD||Change 1h||Change 24h||Change 7d|
|Bitcoin||0.55 %||4.50 %||4.59 %|
|Ethereum||0.87 %||3.18 %||3.19 %|
|XRP||0.78 %||2.27 %||0.07 %|
|Bitcoin Cash||0.91 %||1.29 %||6.52 %|
|Bitcoin SV||1.83 %||6.55 %||0.81 %|
|Tether||0.12 %||0.11 %||0.09 %|
|EOS||0.51 %||7.21 %||11.36 %|
|Litecoin||1.01 %||6.45 %||5.12 %|
|Binance Coin||0.67 %||1.76 %||2.46 %|
|Cardano||0.21 %||0.86 %||4.13 %|
|Ethereum Classic||1.23 %||8.62 %||21.40 %|
|Stellar||0.89 %||1.85 %||4.74 %|
|Monero||0.52 %||2.34 %||1.41 %|
|TRON||1.46 %||3.84 %||5.04 %|
|Tezos||0.03 %||0.94 %||4.63 %|
|Dash||0.75 %||2.42 %||3.34 %|
|ChainLink||0.58 %||0.83 %||3.09 %|
|LEO Token||0.37 %||0.06 %||3.47 %|
|OKB||0.65 %||3.37 %||2.15 %|
|Cosmos||0.09 %||0.78 %||0.33 %|